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Abstract  Article Info 
Introduction: The National Comprehensive Cancer Network recommends induction chemotherapy and 
concurrent chemoradiotherapy as one of the standard therapy for stage II-IVA nasopharyngeal cancer. The use 
of induction chemotherapy given before radiotherapy is an effective treatment strategy because it has a better 
level of adherence and facilitates early eradication of micro metastasis. Chemotherapy has a direct side effect 
of disruption of erythrocyte formation in the bone marrow and reduces the erythropoietin hormone in the kidney. 
Decreased hemoglobin levels exacerbate oxygen deficiency in tumours thereby increasing hypoxic cells and 
contributing to the development of radiotherapy resistance. 
Objective: This research was conducted to find out the hemoglobin levels before and after chemotherapy 
(cisplatin-paclita). An analytical observational study with cross sectional method. The subjects were 36 
nasopharyngeal cancer patients that gone through 6 cycles of chemotherapy and meets the research criteria.xel 
in nasopharyngeal cancer patients. 
Methods: An analytical observational studies with  cross sectional method. The subjects were 36 
nasopharyngeal cancer patients that gone through 6 cycles of chemotherapy and meets the research criteria. 
Results: The results of the bivariate analysis showed differences in the average of hemoglobin levels before and 
after chemotherapy, the average hemoglobin levels before chemotherapy which were 13.39 g/dL and after 
chemotherapy which were 11.35 g /dL in nasopharyngeal cancer patients at Prof. Dr. Margono Soekarjo Hospital 
(P=0,001). 
Conclusion: There is a significant difference between hemoglobin levels before and after chemotherapy 
(cisplatin-paclitaxel) in nasopharyngeal cancer patients in Prof. Dr. Margono Soekarjo Hospital. 
Article history:  
Received: 7 November 2020 
Received in revised form 28 November 2020 
Accepted 7 December 2020 
 
Keywords:  
Hemoglobin, chemotherapy, nasopharyngeal 
cancer 
*Corresponding author:  
Sekti Joko Suntono Islamanto 
Address: Jl. Dr. Soeparno, Kampus 
Karangwangkal Gedung E, Karang Bawang, 
Grendeng, Kec. Purwokerto Utara, Kabupaten 




The definition of nasopharyngeal cancer is squamous cell carcinoma 
arising from nasopharyngeal epithelium, futhermore the disease is bounded 
by geographical and racial distribution [1]. Globally, there are 80.000 new 
cases reported annually related to nasopharyngeal cancer [2]. Data in 2012 
shows five countries that had the most deaths due to nasopharyngeal cancer 
were China (21,300 deaths), Indonesia (7,391 deaths), Vietnam (2,885 
deaths), India (2,836 deaths), and Thailand (1,141 cases) [3]. The Global 
Cancer Observatory (GLOBOCAN) recorded in 2018 there were 17,992 
new cases of nasopharyngeal cancer and the death rate reached 1,204 cases 
in Indonesia. Nasopharyngeal cancer occupies at the top 5 most frequently 
found new cancer cases in men, as many as 13,966 cases (8.7 %) in 2018 
[4]. New nasopharyngeal cancer cases reported at RSUP Dr. Kariadi 
Semarang as many as 127 cases in the span years of 2000 to 2002 [5], had 
increased to 141 cases in 2014-2016 [6]. In Prof. Dr. Margono Soekarjo 
Hospital, nasopharyngeal cancer is the second most common type of 
malignancy found after cervical cancer [7]. Nasopharyngeal cancer cases in 
Prof. Dr. Margono Soekarjo Hospital reported as many as 497 cases in the 
span years of 2007 to 2016 [8]. 
Nasopharyngeal cancer therapy based on the National Comprehensive 
Cancer Network (NCCN) recommends induction chemotherapy and 
concurrent chemoradiotherapy as one of the standard treatments for stage 
II-IVA nasopharyngeal cancer. The use of induction chemotherapy given 
before radiotherapy is an effective treatment strategy because it has a better 
level of adherence and facilitates early eradication of micrometastasis [9]. 
Chemotherapy drugs are more effective when used in combination. 
Combination regimens that can be given with the platinum group include 5-
fluorouracil, paclitaxel, and docetaxel. Combination cisplatin-paclitaxel 
chemotherapy produces higher clinical response rates than other drug 
combinations in particular [10]. 
Chemotherapy is a cytotoxic drug that has known to have 
myelosuppression side effects [11]. Chemotherapy cytotoxic agents can 
induce anemia through direct disorders of hematopoiesis, including the 
synthesis of erythrocyte precursors in the bone marrow and reducing 
erythropoietin production the kidney [12]. 
Decreased hemoglobin (Hb) levels might exacerbate oxygen deficiency 
in tumors thereby increasing hypoxic cells and contributing to the 
development of radiotherapy resistance. Low Hb levels have been reported 
as adverse factors in the management of radiotherapy from various tumors 
(ex., head and neck squamous cell cancer, cervical cancer, lung cancer, and 
bladder cancer) [13]. The lack of radiation optimization results in the repair 
of cancer cells that cause the therapeutic process becomes ineffective both 
technically, clinically, and economically. Anemia is dangerous state in 
patients as it has a higher risk of death rather than non anemic patients [14]. 
Thereafter, hemoglobin levels after chemotherapy induction can influence 
the choice and the outcome of further therapy. The authors expect the results 
of this study can serve as initial research on one of the side effects of 
chemotherapy combination, especially in bone marrow suppression by 
looking at hemoglobin levels in nasopharyngeal cancer patients. 
2. MATERIALS AND METHODS 
This observational analytic study was using cross sectional method 
with simple random sampling technique. The study was conducted 
using secondary data obtained from the ENT Installation of Prof. Dr. 
Margono Soekarjo Hospital from 2014 to 2019. Samples included in 
this study were stage II-IVA nasopharyngeal cancer patients who 
received combination chemotherapy cisplatin-paclitaxel within a period 
of 6 cycles. Criteria for exclusion of the study includes patients who 
were treated for radiation within 4 months before the initiation of 
chemotherapy, as well as incomplete medical record data of patients. 







Data were analyzed using the SPSS program ver. 25. Bivariate analysis 
using paired t-test design with the aim of knowing the effects of 
chemotherapy in hematological toxicity, especially hemoglobin levels. 
The results are significant if P<0.05 was obtained.  
3. RESULTS 
This research data (36 samples) were obtained from medical 
records of nasopharyngeal patients who received cisplatin-paclitaxel 
chemotherapy in 2014 to 2019. Data collected were Hb levels, age, sex, 
nutritional status (BMI Score), and type of nasopharyngeal cancer 
obtained from medical record data. 
Table 1. Baseline Characteristics of Research Subjects  
Characteristics Total (N=36) Mean±SD P-value  















1.61±0.494 0.000  
NPC Type, n (%) 
WHO type I 
WHO type II 





2.78±0.422 0.000  
BMI, n (%)  1.83±0.507 0.000  
Underweight 8(22.2)   
Normal 26(72.6)   
Overweight 2(5.6)   
Obese 0 
Hb Levels    
Before 36 13.397±2.0817 0.691  
After 36 11.350±0.9467 0.178  
Data distribution using the Shapiro-Wilk method shows Hb before 
chemotherapy (P=0.691) and Hb after chemotherapy (P=0.178). The data 
shows P>0.05 for Hb before and after chemotherapy, so it can be concluded 
that the Hb data before and after cis-pac chemotherapy in nasopharyngeal 
cancer patients were normally distributed. The results of the bivariate Paired 
Sample T-Test are displayed in the form of a mean, standard deviation, and 
p-value of hemoglobin levels shown in table 2. 




Hb Levels Before 13.397±2.0817  
Hb Levels After 11.350±0.9467  
Hb Before & After 2.0472±1.9726 0.001  
Based on table 4, the mean Hb level in nasopharyngeal cancer patients 
before chemotherapy is 13,397 g/dL, with a minimum level of 9.3 g/dL and 
a maximum level of 18.5 g/dL. The mean Hb level in nasopharyngeal cancer 
patients after chemotherapy is 11.35 g/dL with a minimum level of 9.5 g/dL 
and a maximum level of 14.1 g/dL. After being tested using Paired Sample 
T-Test the results were P=0.001 (P <0.05). 
4. DISCUSSION 
Kumar et al. reseach on ovarian cancer therapy shows differences in 
hemoglobin levels before the first and after the sixth chemotherapy were 
because of how paclitaxel and cisplatin were cytotoxic drugs that induced 
myelosuppression by directly impairing hematopoiesis in the bone marrow 
[15]. Cisplatin enters the bone marrow cells passively through an 
intracellular transport mechanism. Cisplatin increase ROS production in 
cells and accumulation of ROS will induce cytochrome-c release from 
mitochondria through activation of c-Jun-N-terminal kinase and protein 38 
Mitogen-activated protein kinase [16]. Cisplatin causes damage to the 
mitochondria through the mechanism of crosslinking in the DNA and thus 
interferes with cell replication and transcription. Cytochrome-c then 
activates caspases 8, 9, and 3 which cause apoptosis or disruption of bone 
marrow progenitor cell development. These developmental disorders will 
cause side effects in the form of decreased production of hematopoietic 
cells, which will ultimately affect the production of hemoglobin, leukocytes, 
and platelets [17]. 
Paclitaxel enters blood vessels and immediately distributed to target 
organs including the bone marrow compartment. Paclitaxel will penetrate 
the bone marrow cell membrane and interact with regulatory molecules in 
the cytoplasm then induce p53 and Cyclin Dependent Kinase Inhibitors in 
the nucleus thereby inhibiting cell proliferation. An increase in pro-
apoptotic factors (Bax, Bak, Bim, Bok, Bad) and a decrease in anti-apoptotic 
factors (Bcl-2 and Bcl-x) in the mitochondria because activation of 
cytochrome-c and caspase 9 resulting in the process of apoptosis or 
disruption of the development of bone marrow progenitor cells. Impaired 
development of progenitor cells will affect the hematopoietic process 
afterall [10]. This study lacks of interpretation of other factor that might 
affect hemoglobin levels such as dietary factors, varieties of ages and 
genders in sample research, etc so further study is needed.  
5. CONCLUSION 
The mean hemoglobin level in nasopharyngeal cancer patients was 
13.397 g /dL before cisplatin-paclitaxel chemotherapy and 11.35 g/dL after 
cisplatin-paclitaxel chemotherapy. There were significant differences in the 
mean hemoglobin levels before and after cisplatin-paclitaxel chemotherapy 
in nasopharyngeal cancer patients at Prof. Dr. Margono Soekarjo Hospital 
(P=0.001).  
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